Latest News

View allAccessAL amyloidosisCAR-TConferencesMPEMyelomaNewsPatient evidenceVideos

EMA CHMP gives positive opinion on belantamab mafodotin combinations for relapsed/refractory myeloma patients

On the 23 May 2025, the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of two belantamab mafodotin combinations for the treatment of patients with relapsed and/or refractory myeloma. The first combination is with bortezomib (a proteasome inhibitor) plus the steroid dexamethasone (BVd) in patients who have received at least one prior therapy.…

Read more

Register now to join the webinar “Living well with AL amyloidosis”

Myeloma Patients Europe (MPE) will host a webinar on “Living well with AL amyloidosis” on Thursday, 5 June 2025 from 17:00 – 18:00 CEST. Aimed at AL amyloidosis patients and patient advocates, the webinar will feature presentations on supportive care for patients. Prof. Dr. Monique Minnema, Haematologist at the University Medical Centre Utrecht, will focus…

Read more

In Memoriam of Reidar Nordby

It is with great sadness that we share the news of the passing of our friend, colleague, and fellow patient advocate, Reidar Nordby. With his passing, Myeloma Patients Europe (MPE) has lost not only a dear friend but also a valued Board member since 2023, who contributed to the growth and development of our organisation.…

Read more

European Commission approves linvoseltamab for the treatment of relapsed and refractory myeloma

On 23th April 2025, the European Commission has granted conditional marketing approval of linvoseltamab to treat adults with relapsed and refractory myeloma. Conditional approval means that linvoseltamab will be reassessed for safety and efficacy when the results of other, larger clinical trials become available. This approval is based on the favourable recommendation issued by the…

Read more

EMA CHMP gives positive opinion on linvoseltamab for relapsed/refractory myeloma patients

On 27th February 2025, the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of linvoseltamab for the treatment of patients with relapsed/refractory multiple myeloma. The CHMP is the European Medicines Agency’s committee responsible for opinions on all issues regarding medicinal products for human use. Based on these opinions, then the European Commission…

Read more
April

May 2026

June
MO
TU
WE
TH
FR
SA
SU
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Events for 1st May
No Events
Events for 2nd May
No Events
Events for 3rd May
No Events
Events for 4th May
No Events
Events for 5th May
No Events
Events for 6th May
No Events
Events for 7th May
No Events
Events for 8th May
No Events
Events for 9th May
No Events
Events for 10th May
No Events
Events for 11th May
No Events
Events for 12th May
No Events
Events for 13th May
No Events
Events for 14th May
No Events
Events for 15th May
No Events
Events for 16th May
No Events
Events for 17th May
No Events
Events for 18th May
No Events
Events for 19th May
No Events
Events for 20th May
No Events
Events for 21st May
No Events
Events for 22nd May
No Events
Events for 23rd May
No Events
Events for 24th May
No Events
Events for 25th May
No Events
Events for 26th May
No Events
Events for 27th May
No Events
Events for 28th May
No Events
Events for 29th May
No Events
Events for 30th May
No Events
Events for 31st May
No Events